IsoRay, Inc. (AMEX:ISR) will be hosting a conference call at 4:30 PM eastern time on 10th November 2020, to discuss its 1Q21 financial results with the investment community.
A live webcast with presentations will be available on the Internet by visiting the Company website www.isoray.com
Earnings Expectation
IsoRay, Inc. is reporting first quarter earnings results on Tuesday 10th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.01 per share from $ 2.85 million in revenue. For the full year, analysts predict revenues of $ 12.24 million, while looking forward to loss of $ 0.04 per share.
The Company Outlook
Revenue for 1Q21 are expected in a range of $ 2.30 million ~ $ 2.50 million
Click Here For More Historical Outlooks Of IsoRay, Inc.
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed.
